NRX Pharmaceuticals (NRXP) Preferred Stock Liabilities (2017 - 2019)

NRX Pharmaceuticals (NRXP) has 3 years of Preferred Stock Liabilities data on file, last reported at $24.5 million in Q4 2019.

• On a quarterly basis, Preferred Stock Liabilities fell 62.04% year-over-year to $24.5 million in Q4 2019; TTM through Dec 2019 was $24.5 million, a 62.04% decrease from a year earlier, with the FY2019 full-year figure at $24.5 million, down 62.04% from the prior year.
• Preferred Stock Liabilities for Q4 2019 stood at $24.5 million, down from $34.3 million in the prior quarter.
• Over the last five years, Preferred Stock Liabilities for NRXP reached as high as $64.7 million in Q1 2019 and fell as low as $24.5 million in Q4 2019.
• Historically, Preferred Stock Liabilities has averaged $54.3 million across 3 years, with a median of $64.5 million in 2018.
• On a YoY basis, Preferred Stock Liabilities climbed as much as 0.37% in 2019 and fell as far as 62.04% in 2019.
• Year by year, Preferred Stock Liabilities stood at $64.5 million in 2017, then gained by 0.1% to $64.5 million in 2018, then plunged by 62.04% to $24.5 million in 2019.
• Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $24.5 million in Q4 2019, $34.3 million in Q3 2019, and $43.0 million in Q2 2019.